Publications

  1. Salmasi S, Kwan L, MacGillivray J, Bansback N, De Vera M, Barry AR, Harrison MJ, Andrade J, Lynd LD, Loewen PS, Assessment of atrial fibrillation patients’ education needs from patient and clinician perspectives: a qualitative descriptive study. Thrombosis Research [in press]
  2. Loewen PS, Kapanen A, Ji AT, McClean A. Patient Values and Preferences for Antithrombotic Therapy in Atrial Fibrillation: A Systematic Review. Thrombosis & Haemostasis 2017;117(6):1007-1022. DOI: 10.1160/TH16-10-0787 
  3. Edwards NT, Greanya ED, Kuo IF, Loewen PS, Culley CL. Patient preferences regarding atrial fibrillation stroke prophylaxis in patients at potential risk of atrial fibrillation. International Journal of Clinical Pharmacy 2017; 28: 973–1. 
  4. Loewen P, Gamble A, Shah K, Tkachuk S, Legal M, Zed PJ.  Learner-Preceptor Ratios for Practice-Based Learning Across Health Disciplines: A Systematic Review. Medical Education 2016;51:146–57.
  5. Loewen P, Gerber P, MacDonald G, McCormack J. Design and implementation of an integrated medication management curriculum in an entry-to-practice doctor of pharmacy program. Pharmacy Education 2016;16(1):122-130.
  6. Dahri K, Gong Y, Loewen P. A quantitative and qualitative assessment of the utilization of mobile computing devices by clinical pharmacists. Health Policy and Technology 2016;5:285-290.
  7. Loewen P, Mills A, Harder C, Walus AN, Woloschuk DMM. Should the Postgraduate Year 2 (PGY-2) Residency Be Focused on Advanced Pharmacy Practice Training? Canadian Journal of Hospital Pharmacy 2015;23;68(6):485-488.
  8. Tejani AM, Loewen P, Bachand R, Harder CK. Pharmacists’ Perceptions of the Influence of Interactions with the Pharmaceutical Industry on Clinical Decision-Making. Canadian Journal of Hospital Pharmacy 2015;68(5):378–85. 
  9. Bolt J, Semchuk B, Loewen P, Bell A, Strugari C. A Canadian survey of pharmacist participation during cardiopulmonary resuscitation. Canadian Journal of Hospital Pharmacy 2015;68:290-5.
  10. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD008772. DOI: 10.1002/14651858.CD008772.pub2
  11. Loewen, P. Are the New Guidelines for the Use of Lipid-Lowering Agents Sound, and Should Their Adoption Be Encouraged? Canadian Journal of Hospital Pharmacy 2014;67(3):256-7.
  12. Loewen P. Ethical Issues in Pharmacy Practice Research: An Introductory Guide. Canadian Journal of Hospital Pharmacy 2014;67(2), 133–137. 
  13. Loewen P, Jelescu-Bodos A, Yeung J, Lau T. The Effect of Transitioning from Residency to Pharmacy Practice on Learning Style. American Journal of Pharmaceutical Education 2014;78(8):Article 147.
  14. Power J, Spina SP, Forbes DA, Harder CK, Loewen PS, Zed PJ, Lalli SL. Integration of smartphones into clinical pharmacy practice: An evaluation of the impact on pharmacists׳ efficiency. Health Policy and Technology 2014;3(4):296–305.
  15. Loewen P, de Lemos J, Woo S. Clinician-driven value scoring to prioritise quality actions: a study of general medicine hospital pharmacists. Journal of Pharmaceutical Health Services Research 2014;5(2):103-108.
  16. Loewen P, Jelescu-Bodos A. Learning Styles and Teaching Perspectives of Canadian Pharmacy Practice Residents and Faculty Preceptors. American Journal of Pharmaceutical Education. Am J Pharm Educ 2013;77(8):Article 163.
  17. Taylor R, Jung J, Loewen P, Spencer C, Dossa A, de Lemos J. Online versus Live Delivery of Education to Pharmacists in a Large Multicentre Health Region: A Non-inferiority Assessment of Learning Outcomes. Canadian Journal of Hospital Pharmacy 2013;66:233-40. 
  18. Chernushkin K, Loewen P, Jung J, Dahri K, Aulakh A, de Lemos J. Diagnostic reasoning by hospital pharmacists: Assessment of attitudes, knowledge, and skills. Canadian Journal of Hospital Pharmacy 2012;65(4):258–264.
  19. Ariano RE, Loewen P. Should all pharmacists responsible for pharmacotherapeutic management of patients with complex or special drug therapy needs have certification from the board of pharmacy specialties? Canadian Journal of Hospital Pharmacy 2012;65(3):231-233.
  20. Chernushkin K, Loewen P, de Lemos J, Aulakh A, Jung J, Dahri K. Diagnostic reasoning by hospital pharmacists: assessment of attitudes, knowledge, and skills. Can J Hosp Pharm 2012;65:258–64. 
  21. Barry AR, Loewen P, de Lemos J, Lee KG. Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development. J Eval Clin Pract 2012;18:49–55. 
  22. Buna DK, McGloin R, Loewen P, Thornhill AK, Dillon ED, Hawkes J. Survey of graduates of the british columbia pharmacy practice residency programs, 1973-2009. Can J Hosp Pharm 2011;64:419–25.
  23. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann. Hematol. 2011;90:1191–200.
  24. Bruchet N, Loewen P, de Lemos J. Improving the quality of clinical pharmacy services: a process to identify and capture high-value "quality actions". Can J Hosp Pharm 2011;64:42–7. 
  25. Schwenger EM, Tejani AM, Loewen P. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database of Systematic Reviews 2010;
  26. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen P, Purssell RA. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med 2010;55:493–4. 
  27. Mountford CM, Lee T, de Lemos J, Loewen P. Quality and usability of common drug information databases. Can J Hosp Pharm 2010;63:130–7. 
  28. Loewen P, Merrett F, LEMOS JD. Pharmacists' perceptions of the impact of care they provide. Pharmacy Practice  2010;
  29. Loewen P. Should a Process be Developed to Recognize “Pharmacy Practice Residency Equivalency” for Pharmacists with Substantial Clinical Experience Who Have Not …. Can J Hosp Pharm 2010;63:30–1. 
  30. Barry AR, Loewen P, de Lemos J, Lee KG. Reasons for Non-use of Proven Interventions for Hospital Inpatients: Pharmacists' Perspectives. Can J Hosp Pharm 2009;62:381–5. 
  31. Loewen P. Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours? Can J Hosp Pharm 2009;62:248–51. 
  32. Huang C, Loewen P, Pelletier T, Slater J, Chung M. Implementation of proven interventions in general medical inpatients: development and evaluation of a new quality indicator for drug therapy. Qual Saf Health Care 2008;17:269–74. 
  33. Zed PJ, Abu-Laban RB, Balen RM, Loewen P, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008;178:1563–9. 
  34. Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb. Haemost. 2007;98:980–7. 
  35. McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. Can Fam Physician 2007;53:1326–7. 
  36. Patel K, Loewen P, Wilbur K. A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients. The Canadian Journal of Hospital … 2006;
  37. Saran MK, Loewen PS, Zed PJ. Opportunities for optimizing pantoprazole therapy in patients with acute upper gastrointestinal bleeding. Hospital Pharmacy 2006;
  38. McCormack JP, Loewen P. The other side of the bezafibrate infarction prevention trial data. Arch. Intern. Med. 2005;165:2431–2–authorreply2432. 
  39. Raybardhan S, Balen RM, Partovi N, Loewen P, Liu G, Jewesson PJ. Documenting drug-related problems with personal digital assistants in a multisite health system. Am J Health Syst Pharm 2005;62:1782–7. 
  40. McCormack JP, Loewen P, Jewesson PJ. Dissemination of results needs to be tracked as well as the funding is. BMJ 2005;331:456. 
  41. McCormack JP, Loewen P. Misplaced allegations. CMAJ 2004;170:1207–7. 
  42. Sprague DA, Loewen P, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother 2004;38:313–9. 
  43. Loewen P, Lamb S, Clugston P. Randomized, double-blind trial of dolasetron versus droperidol for prophylaxis of postoperative nausea and vomiting in patients undergoing TRAM flap breast reconstruction surgery. Ann Plast Surg 2003;51:472–7. 
  44. Zed PJ, Rowe BH, Loewen P, Abu-Laban RB. Systematic reviews in emergency medicine: Part II. Critical appraisal of review quality, data synthesis and result interpretation. CJEM 2003;5:406–11. 
  45. Zed PJ, Rowe BH, Loewen P, Abu-Laban RB. Systematic reviews in emergency medicine: Part I. Background and general principles for locating and critically appraising reviews. CJEM 2003;5:331–5. 
  46. Sprague DA, Loewen P. Bedside calculation of stroke risk in patients with atrial fibrillation. Am J Health Syst Pharm 2003;60:427–9. 
  47. Zed PJ, Loewen P, Jewesson PJ. A response to the ACP-ASIM position paper on pharmacist scope of practice. Am J Health Syst Pharm 2002;59:1453–6. 
  48. Loewen P. Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. CJEM 2002;4:268–75. 
  49. Loewen P. Anti-emetics in development. Expert Opin. Investig. Drugs 2002;11:801–5. 
  50. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001;35:1528–34. 
  51. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927–36. 
  52. Loewen PS, Marra CA, Zed PJ. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth 2000;47:1008–18. 
  53. Frighetto L, Loewen P, Dolman J, Marra CA. Cost-effectiveness of prophylactic dolasétron or droperidolvs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Can J Anesth/J Can Anesth 1999;46:536–43. 
  54. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme disease. Drugs 1999;57:157–73. 
  55. Loewen P, Marra F, Marra CA. Influence of the Methods of Reporting Clinical Trial Results on Pharmacists' Willingness to Recommend Drug Therapy. Can J Hosp Pharm 1999;52:145–9. 
  56. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33:61–72. 
  57. Esmail ZN, Loewen PS. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Ann Pharmacother 1998;32:1096–8. 
  58. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Canadian Journal of Cardiology 1998;14:717–26.